Top 10 Oncology Capital Raises and Investors in the U.S. – January 1st to March 31st, 2026
Several interesting transactions closed in the Oncology sector over the past quarter. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Adlai Nortye, clinical-stage company that discovers and develops cancer therapies, received approximately $140.00 million of development capital from Cormorant Asset Management, Casdin Capital, Columbia Threadneedle Investments, Balyasny Asset Management, Point72 Asset Management, and Squadron Capital Management through a private placement.
- AN2 Therapeutics, biopharmaceutical company that discovers and develops novel small molecule therapeutics derived from its boron chemistry platform, received an estimated $23.5 million of development capital from Coastlands Capital LP, Commodore Capital and Vivo Capital through a private placement.
Merger/Acquisition
-
- Hera BioLabs, pre-clinical drug development services that develops cell-line modification and animal model creation, was acquired by Demeetra.
- Ouro Medicines, innovative therapeutics that treats immune-mediated diseases by targeting underlying immune system dysfunction, was acquired by Gilead for $1.675 billion.
Later Stage VC
-
- Embolx, medical devices for arterial embolization procedures, raised venture funding from MedTech Angels.
- Exact Imaging, high-resolution micro-ultrasound systems for real-time prostate imaging and biopsy guidance, raised $10 million of venture funding in a deal led by iGan Partners.
Early Stage VC
-
- Nexo Therapeutics, molecule oncology platform that advances the development of small-molecule therapies for patients with limited treatment options, raised $60 million of Series A venture funding through a combination of debt and equity in a deal led by Versant Ventures.
- NOXX Therapeutics, monoclonal antibodies and conjugates that targets a clinically validated pathway responsible for tumor-induced immune suppression, raised $1 million of venture funding.
Seed
-
- Advac Therapeutics, vaccines and therapeutics for the treatment of infectious diseases and cancers, raised $500,000 of seed funding.
- ImmuneBridge, allogeneic cellular immunotherapies for advancing cancer treatment, raised $7.7 million of seed funding in a deal led by NFX.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
